Holders — by stockHoldings — by fund
Ishara Investments LP
Everything this manager disclosed owning in US-listed stocks — its complete Form 13F portfolio · as of 2026-06-30 · filed with the SEC up to 45 days after quarter end · CIK 2111609
$136.1M
disclosed book value
41
positions
7.6%
largest position share
Positions, as of 2026-06-30
top 41 of 41 · 13F covers long US-listed positions only — cash, bonds, private and foreign stakes are not disclosed · PUT/CALL tags = options positions (share-equivalents), not shares held
| # | Issuer | Shares | Value | % of book |
|---|---|---|---|---|
| 1 | ACADACADIA PHARMACEUTICALS INC | 410,000 | $10.4M | 7.6% |
| 2 | XERSXERIS BIOPHARMA HOLDINGS INC | 1.2M | $9.7M | 7.2% |
| 3 | BMRNBIOMARIN PHARMACEUTICAL INC | 143,500 | $8.2M | 6% |
| 4 | PRAXPRAXIS PRECISION MEDICINES I | 22,550 | $7.5M | 5.5% |
| 5 | RAREULTRAGENYX PHARMACEUTICAL IN | 205,000 | $6.8M | 5% |
| 6 | AGIOAGIOS PHARMACEUTICALS INC | 164,000 | $6.1M | 4.5% |
| 7 | INSMINSMED INC | 51,250 | $5.5M | 4% |
| 8 | CRNXCRINETICS PHARMACEUTICALS IN | 143,500 | $5.4M | 3.9% |
| 9 | ZNTLZENTALIS PHARMACEUTICALS INC | 1.0M | $5.0M | 3.7% |
| 10 | PCVXVAXCYTE INC | 82,000 | $4.8M | 3.5% |
| 11 | ANNXANNEXON INC | 820,000 | $4.7M | 3.4% |
| 12 | TVTXTRAVERE THERAPEUTICS INC | 82,000 | $4.7M | 3.4% |
| 13 | TNXPTONIX PHARMACEUTICALS HLDG C | 338,250 | $4.3M | 3.2% |
| 14 | BBIOBRIDGEBIO PHARMA INC | 57,400 | $4.3M | 3.1% |
| 15 | AXSMAXSOME THERAPEUTICS INC. | 16,400 | $4.0M | 2.9% |
| 16 | CTNMCONTINEUM THERAPEUTICS INC | 205,000 | $3.4M | 2.5% |
| 17 | LXRXLEXICON PHARMACEUTICALS INC | 1.3M | $3.1M | 2.2% |
| 18 | KURAKURA ONCOLOGY INC | 276,750 | $3.0M | 2.2% |
| 19 | DBVTDBV TECHNOLOGIES S A | 184,500 | $3.0M | 2.2% |
| 20 | GMABGENMAB A/S | 102,500 | $2.8M | 2.1% |
| 21 | CYTKCYTOKINETICS INC | 32,800 | $2.8M | 2.1% |
| 22 | MLYSMINERALYS THERAPEUTICS INC | 102,500 | $2.8M | 2% |
| 23 | SLNSILENCE THERAPEUTICS PLC | 55,350 | $2.4M | 1.8% |
| 24 | NUVBNUVATION BIO INC | 369,000 | $2.1M | 1.5% |
| 25 | WAVE LIFE SCIENCES LTD | 328,000 | $1.9M | 1.4% |
| 26 | NKTRNEKTAR THERAPEUTICS | 26,650 | $1.9M | 1.4% |
| 27 | SRRKSCHOLAR ROCK HLDG CORP | 30,750 | $1.7M | 1.2% |
| 28 | ELVNENLIVEN THERAPEUTICS INC | 32,800 | $1.7M | 1.2% |
| 29 | ALNYALNYLAM PHARMACEUTICALS INC | 5,125 | $1.5M | 1.1% |
| 30 | BEAMBEAM THERAPEUTICS INC | 41,000 | $1.4M | 1% |
| 31 | SIONSIONNA THERAPEUTICS INC | 123,000 | $1.4M | 1% |
| 32 | ORICORIC PHARMACEUTICALS INC | 123,000 | $1.3M | 1% |
| 33 | NEWAMSTERDAM PHARMA COMPANY | 36,900 | $1.3M | 0.9% |
| 34 | VRTXVERTEX PHARMACEUTICALS INC | 2,460 | $1.2M | 0.9% |
| 35 | SPRYARS PHARMACEUTICALS INC | 143,490 | $1.1M | 0.8% |
| 36 | MNPRMONOPAR THERAPEUTICS INC | 12,300 | $1.1M | 0.8% |
| 37 | ERASERASCA INC | 41,000 | $751,120 | 0.6% |
| 38 | VERAVERA THERAPEUTICS INC | 10,250 | $439,828 | 0.3% |
| 39 | IMMATICS N.V | 30,750 | $311,498 | 0.2% |
| 40 | MREOMEREO BIOPHARMA GROUP PLC | 768,750 | $244,232 | 0.2% |
| 41 | GOSSGOSSAMER BIO INC | 820,000 | $134,972 | 0.1% |
Source: SEC Form 13F-HR, reporting period 2026-06-30. Values are the manager's filed June-30-style quarter-end marks, not live prices. Research, not investment advice.